Background: It is largely unknown if anti-HPV serum antibody responses vary by anatomic site
INTRODUCTION
Human Papillomavirus (HPV) infection has been established as the cause of cervical, anal, penile, vaginal and vulvar cancers, and a subset of head and neck cancers (1). Detection of HPV infection at multiple anatomic sites is not uncommon in healthy adults and has been reported in a number of large epidemiologic studies (2, 3) . A fundamental question is whether serum antibody responses vary by anatomic site of HPV infection. Answers will further our understanding of differences in population seroprevalence related to gender and sexual orientation.
Consistent gender gaps in population seroprevalence have been well documented (4) . Studies have also shown that men who practice same-sex intercourse have higher seroprevalence of vaccine HPV types (HPV 6, 11, 16, and 18) than do those with heterosexual relationship, suggesting differences in anatomic site infected with HPV may be relevant (5) (6) (7) . The present study assesses type-specific vaccine HPV seroprevalence in association with corresponding HPV DNA detection at two different anatomic sites in men, the external genitalia and the anal canal, to determine whether anti-HPV serum antibody status varies by anatomic site of infection. Due to the sparse data for HPV 11 and 18, the current report only includes data for HPV 6 and 16.
METHODS

Study Population.
We analyzed enrollment data from the HIM Study, an ongoing multi-national HPV natural history study in men conducted in Tampa, United States, São Paulo, Brazil, and Cuernavaca, Mexico. Details of the study cohort have been described elsewhere (8) .
In brief, healthy men were recruited using the following inclusion criteria: ages 18-70 years; residents of one of the 3 study sites; no prior diagnosis of penile and anal cancers or genital warts; no symptoms of or current treatment for sexually transmitted infections (STIs) including HIV/AIDS; no concurrent participation in an HPV vaccine study; and no history of imprisonment, homelessness or drug treatment in the past 6 months. At enrollment participants were adminis- men and MSM who also had survey information, serology and genital HPV DNA results available from the enrollment visit were included in the current analysis. To assess potential selection bias stemming from optional anal sampling we compared characteristics of men included in the current analysis with those in the full HIM study cohort. We observed no differences in terms of demographics, life styles or sexual behaviors in the current study cohort, although the current participants were slightly older (p=0.002) and more likely to report one or no recent female sex partners (p=0.002) (Supplementary data).
HPV Serum Antibody Testing. Testing of anti-HPV serum antibodies was performed using virus-like particle (VLP)-based enzyme-linked, immunosorbent assays (ELISA) (9) . Specimens were tested in duplicate on separate plates, with retesting of specimens showing results exceeding a preset, acceptable coefficient of variation (CV) of 25%. Seroreactivity was measured by absorbance values expressed in optical density (OD). The mean and standard deviation (SD) of absorbance values were estimated based on seroreactivity of sera from children ages 0-10 years. Five standard deviations above the mean absorbance value was used as the cut point to determine seropositivity. Quality control of the serology assays was assured by inclusion of laboratory-prepared positive and negative controls in each run of the assay. HPV DNA Sampling and Testing. Three pre-wetted swabs were used to collect exfoliated skin cells from the penis (coronal sulcus; glans; and ventral and dorsal areas of shaft) and scrotum, and later combined to form a single specimen. Using a new swab, exfoliated cells were collected from between the anal os and the dentate line and placed into standard transport medium as a separate specimen. All specimens were stored at -80°C until use. DNA was extracted from exfoliated skin cell samples using the QIAamp DNA Mini Kit (QIAGEN, Valencia, CA) and tested for HPV DNA using PGMY 09/11 consensus primer system. The Linear Array Genotyping Protocol (Roche Diagnostics, Indianapolis, IN) was applied to detect 37 genital HPV types.
Presence of human β-globin was tested to assure sample adequacy and was detected in both genital and anal HPV DNA samples in 82% of 1786 men.
Statistical Analysis. Participants were classified as men who had sex with women (MSW, n=1587, 88.9%), men who had sex with men (MSM, n=99, 5.5%), and men who had sex with men and women (MSMW, n=100, 5.6%) based on their responses to multiple baseline survey questions regarding their recent and lifetime sexual behaviors. Given the small number of MSM and MSMW, and their shared practice of same-sex sexual behaviors, MSM and MSMW were combined into the group "MSM" in the current analysis. Four categories of anogenital HPV DNA status were defined on a type-specific basis: HPV positive at both the anal canal and external genitalia (anal+/genital+), positive at the anal canal only (anal+/genital-), positive at the external genitalia only (anal-/genital+), and HPV negative at both sites (anal-/genital-). Serum antibody levels corresponding to site-specific anogenital infections were compared on a pairwise manner using Wilcoxon rank-sums test. The 95 percent confidence intervals (95% CI) of seroprevalence were estimated following a binomial distribution. A modified Poisson regression approach was used to estimate the associations between seroprevalence and anogenital HPV DNA status, measured by prevalence ratio (PR) and its 95% CIs (10 The association of HPV seropositivity with anogenital HPV DNA detection was determined on a type-specific basis (Table 1) 
DISCUSSION
To our knowledge, this study is the first to examine the likelihood of seropositivity in association with HPV DNA detection at multiple anatomic sites in men. Our data show that serum antibody levels and seroprevalence of HPV 6 and 16 were consistently higher in men with corresponding anal HPV infection, regardless of genital co-infection, compared to men with genital HPV infection alone. In addition, seroprevalence was higher in MSM than in heterosexual men who had same HPV DNA detected at the same anatomic site. Furthermore, we showed that HPV 6 seropositivity was strongly associated with concurrent detection of anal HPV 6 DNA, but not concurrent detection of genital HPV 6 DNA alone, in both MSW and MSM. Independent associations between HPV 16 seropositivity and anal HPV 16 DNA detection were only observed in MSM.
Our finding is consistent with previous observations that HPV seroprevalence was not associated with concurrent detection of genital HPV DNA in healthy adults (5, 11, 12) . Given the lower incidence of HPV 6 infection in the anus compared to the external genitalia (1.2 vs. 3.6 per 1000 person-months), and relatively comparable clearance at both sites (64.7% at 6-month visit vs. 50% at 6.4 months) previously reported for the HIM Study participants (8, 13), higher HPV 6 seroprevalence in men with anal HPV 6 infection compared to those with genital HPV 6 infection alone observed in the current study is unlikely caused by differences in acquisition and specific HPV DNA detection in men may be explained by the type of epithelium present at each anatomic site. Antigen presentation to the immune system at a mucosal epithelium (e.g. anus, cervix), compared to that at a keratinized epithelium (e.g. shaft, glans in circumcised men), may provide more direct access to the lymphatics and draining lymph nodes where immune responses are initiated, resulting in earlier and stronger antibody responses (14) . Furthermore, the histology of the anal canal closely resembles that of the cervix with a transformation zone (15) .
The similarity in anatomy of the cervix and the anus suggests that divergent seroprevalence ob- A. Anti-HPV 6 serum antibody levels in MSW B. Anti-HPV 6 serum antibody levels in MSM 
